Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (June 2022)
34 slides from Painchek's investor presentation, Jun 24, 2022
Slide 1: Capital Raising and Investor Presentation June 2022
For personal use only Capital Raising and Investor Presentation June 2022 PH I LI P D AFF AS, PAI N C H EK LTD C EO & M D ASX:PC K 1 |
Slide 2: Corporate Overview
CORPORATE OVERVIEW For personal use only • PainChek’s SAAS AI Platform uses smart devices to accurately evaluate patients’ pain levels • PainChek improves Patient care – and saves time and money for providers • 126,000 contracted beds across 1,500 facilities globally - 60% market share in Australia,
Slide 3: Our purpose is to give a voice to people who cannot reliably verbalise their pain
Our purpose is to give a voice to people who cannot reliably verbalise their pain For personal use only 3 |
Slide 4: The Breadth of the PainChek Global Market Opportunity
THE BREADTH OF THE PAINCHEK GLOBAL MARKET OPPORTUNITY For personal use only 400Mpre-verbal children 25-42% of hospital beds occupied by people with dementia 57M people living with dementia >150M expected by 2050 1. Ecology Communications Group. www.ecology.com/birth-death-rates 2. World Alzheimer Re
Slide 5: PainChek Adult – A Universal Fully Digital Solution
PAINCHEK ADULT – A UNIVERSAL FULLY DIGITAL SOLUTION For personal use only • Mobile point of care and real time pain assessment App • Fully digital technology – from sales, delivery and implementation – to assess pain or document pain for all people, everywhere. • SaaS Business model – B2B annual ent
Slide 6: Key Achievements
KEY ACHIEVEMENTS For personal use only 126,000 global licenses contracted, with an expected ARR of $4.3M within First New Zealand sale rollout started with Summerset 12 months when fully implemented and transitioned - excluding new Holdings. – NZ’s 3rd largest aged care provider business . Adult and
Slide 7: ANZ Sales and Partnership Milestones – FY22 YTD
ANZ SALES AND PARTNERSHIP MILESTONES – FY22 YTD For personal use only Sumerset Group NZ Joondalup Health Finley Regional Care The Nulsen Group contracted for full Campus (Ramsay contracted as contracted as PainChek rollout Health Care) contracted PainChek’s first PainChek’s first as PainChek first c
Slide 8: UK – Rapid Entry into the 440,000 Bed Residential Aged Care Market
UK - RAPID ENTRY INTO THE 440,000 BED RESIDENTIAL AGED CARE MARKET For personal use only “ The greatest achievement to date s a marked decrease in antipsychotic use in those living with dementia. UK market traction Government funded New sales with Care UK Cheryl Baird, Director of Quality growing –
Slide 9: Strong Growth in Customer Revenue
STRONG GROWTH IN CUSTOMER REVENUE For personal use only • Strong increase in Q3 FY22 Customer Revenue over CUSTOMER REVENUE BY QUARTER prior quarter (+ 66%) A$ (Q3 FY22 UNAUDITED) +66% over $350,000 prior quarter • Growth driven by successful conversion of $300,000 government funded users to commerc
Slide 10: Business Growth Reflected in Training & Clinical Use
BUSINESS GROWTH REFLECTED IN TRAINING & CLINICAL USE For personal use only PAINCHEK® USERS NUMBER OF PAINCHEK ASSESSMENTS TRAINED DIGITALLY PER QUARTER 9,000 1,076,714 Cumulative 8,000 250,000 219,747 7,000 204,992 200,000 6,000 172,225 5,000 150,000 126,087 4,000 3,000 100,000 89,011 2,000 50,000 1
Slide 11: Growth in Global Commercial Subscriptions
GROWTH IN GLOBAL COMMERCIAL SUBSCRIPTIONS - DRIVEN BY SUCCESSFUL CONVERSION OF GOVERNMENT FUNDED BEDS For personal use only CONTRACTED AND IMPLEMENTED CONTRACTED AND IMPLEMENTED NUMBER ANNUAL RECURRING REVENUE ($M) 70,000 66,032 $3.5 64,167 $3.1M $3.2M 60,000 $3.0 53,689 $2.6M 46,843 50,000 $2.5 $2.
Slide 12: $4.3m ARR Expected Within 12 Months from Existing Contracts
$4.3m* ARR EXPECTED WITHIN 12 MONTHS FROM EXISTING CONTRACTS For personal use only TRANSITION TO COMMERCIAL CONTRACTS • 91% Retention Rate of commercial (non- govt.) contracts on (NEXT 12 MONTHS) renewal 100,000 ARR ~$4.3 million $4.5 • Government funding ends in January 2023, when users must ~92,00
Slide 13: Integration Partners Providing Access to 470,000 Aged Care Beds
INTEGRATION PARTNERS in Australia, UK, NZ and Canada provide access to more than 470,000 aged care beds For personal use only PainChek works with aged care management and Integration partners support the drive to better care medication management systems covering more delivery and eliminating duplic
Slide 14: Home Care Partners
HOME CARE PARTNERS For personal use only In late 2021, PainChek announced our partnership Many of PainChek’s existing integration partners also with MPS Connect, a subsidiary of Sigma provide service to the large and growing home care Healthcare. market, both in Australia and globally. The PainChek
Slide 15: Rapid Global Market Expansion Strategy
RAPID GLOBAL MARKET EXPANSION STRATEGY For personal use only Residential Home care & aged care direct to carer Leverage existing ANZ base Transition into Home care for Asia market entry through existing RAC clients and integration partners in each market Leverage existing UK base for EU market entry
Slide 16: Infant App Regulatory Cleared for Sale in Multiple Markets
INFANT APP REGULATORY CLEARED FOR SALE IN MULTIPLE MARKETS* For personal use only World first facial recognition UK, CE & TGA clearance for Infant PCK infant clinical study technology to assess pre-verbal version achieved Q2 CY21 published in Lancet Digital infant post-procedural pain US market entr
Slide 17: How PainChek Infant Can Support HCPs & Parents
HOW PAINCHEK® INFANT CAN SUPPORT HCP’s & PARENTS BETTER MANAGE POST PROCEDURAL PAIN FOR INFANTS For personal use only 1. 2. 3. 4. Infant prior to PainChek Infant is Parent can access Parent can utilise vaccination or post available for health care PainChek via retail or PainChek to continually surgi
Slide 18: Integrated Pain Assessment & Medication Management
INTEGRATED PAIN ASSESSMENT & MEDICATION MANAGEMENT TARGET MARKETS For personal use only BUSINESS MODEL TARGET MARKETS/USERS Healthcare Professionals B2B Enterprise licence - Hospitals - Dementia - Care Homes &/geriatric wards - Home care - ER/Post surgical - Primary Care infant care - Residential &
Slide 19: PainChek Strategic Pillars for 2022
PAINCHEK STRATEGIC PILLARS FOR 2022 For personal use only CORE RAC FOCUS ON STRATEGIC NEW MARKET COMMERCIALISATION PRODUCT & GLOBAL EXPANSION OF INFANT APP MARKET ENTRIES • Implement contracted beds • Initial target markets and users: • Build Home Care & Hospital across ANZ and transition govt - Pos
Slide 20: Portfolio Planning and Potential Annual Market Values
PORTFOLIO PLANNING AND POTENTIAL ANNUAL MARKET VALUES PRODUCT PLAN – MAJOR MARKETS 2022-2024 For personal use only GLOBAL ANNUAL TOTAL EXISTING MARKETS 40% GLOBAL ACCESS ADDRESSABLE MARKETS Adult EU, ANZ, CANADA, SINGAPORE, UK universal B2B Residential Aged Care App Enterprise licence 2022/3 2023/4
Slide 21: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished global Jeff is a professor in the School of Pharmacy, Andy is a Psychologist, management
Slide 22: The Board
THE BOARD For personal use only John Murray Chairman John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Venture Philip is a highly Senior global medical Corporate finance exe
Slide 23: Corporate Summary
CORPORATE SUMMARY For personal use only Financial information Share price (21 June 2022) A$0.033 Shares on issue 1,132.6m Market capitalisation A$37.4m Cash (31 March 2021) A$4.7m Unlisted options/performance rights 58.8m Debt Nil Top shareholders % Peters Investments Proprietary Ltd 9.98% Board & k
Slide 24: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only DOMINANT MARKET POSITION STRONG REVENUE GROWTH 60% market share in Australia , accelerating presence Q3 FY22 Customer revenue up 66% on prior quarter to in the UK and New Zealand, 126,000 contracted beds $304k across 1,500 facilities globally ONGOING CONTR
Slide 25: Capital Raising Overview
For personal use only Capital Raising Overview 25 |
Slide 26: Offer Summary
OFFER SUMMARY For personal use only A$4.6 million equity raising comprising: Offer structure • A non-underwritten placement to raise approximately A$3.0 million, utilising the Offeror’s available capacity under ASX Listing Rule 7.1 (“Placement”); and • An underwritten 1 for 20 non-accelerated non-re
Slide 27: Timetable, Sources and Uses
TIMETABLE, SOURCES AND USES For personal use only Item Date Source of Funds Trading Halt Wednesday, 22 June 2022 Placement A$3.0m Announcement of Entitlement Offer and results of Entitlement Offer A$1.6m Placement Friday, 24 June 2022 Total Sources A$4.6m Normal trading resumes 7:00pm (AEST) on Reco
Slide 28: Key Risks
KEY RISKS For personal use only PCK has commenced selling its Adult App in Australia and certain international markets, being the United Kingdom, New Zealand and Singapore. Expansion Successful of PCK's products to international markets is still in early stages and there is no certainty of comparabl
Slide 29: Key Risks
KEY RISKS For personal use only Other companies may develop competing products or services which assess and monitor pain in target market segments. PCK’s failure to compete effectively Competition against existing competitors and potential new entrants could have a material adverse effect on PCK's o
Slide 30: Key Risks
KEY RISKS For personal use only PCK currently has a small team of employees and contractors and depends on key people for its success. There is no certainty that key people can be retained Dependence on or additional resources recruited to execute PCK’s business plans. There is a risk that the depar
Slide 31: Important Notice
IMPORTANT NOTICE This Presentation has been prepared by PainChek Ltd (ACN 146 035 127) ("PainChek" or "Company"). For personal use only Summary Information This Presentation contains selected summary information about PainChek and does not purport to be all inclusive or relevant, or to contain all o
Slide 32: Important Notice (cont.)
IMPORTANT NOTICE (CONT.) General For personal use only The distribution of this Presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply
Slide 33: Important Notice (cont.)
IMPORTANT NOTICE (CONT.) New Zealand (cont.) For personal use only (b) acknowledge that: (i) Part 3 of the FMC Act shall not apply in respect of the offer of New Shares to you, (ii) no product disclosure statement or other disclosure document under the FMC Act may be prepared in respect of the offer
Slide 34: Contact
For personal use only C O N TAC T Phi l ip D a f f a s , C EO & M D phi l ip.daffa s@painche k.com 34 |